INMD InMode Ltd. Annual reports only
Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1742692 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-6.2%
TTM net income YoY-48.2%
TTM EPS YoY-36.4%
Revenue 3-yr CAGR-6.6%
Net income 3-yr CAGR-16.6%
Margins
Gross margin78.5%
Operating margin23.0%
Net margin25.3%
FCF margin22.7%
EBITDA margin23.2%
Returns
ROE13.5%
ROA12.1%
ROIC (approx.)15.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio9.88x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.91x
Accruals ratio1.1%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $370.50M | $394.82M |
| Cost of revenue | $79.53M | $77.75M |
| Gross profit | $290.97M | $317.07M |
| R&D expense | $13.32M | $13.14M |
| SG&A expense | $11.69M | $10.03M |
| Operating income | $85.39M | $112.53M |
| Pretax income | $110.33M | $143.47M |
| Income tax | $16.50M | -$37.81M |
| Net income | $93.83M | $181.28M |
| EBITDA | $86.08M | $113.26M |
| EPS (basic) | 1.45 | 2.29 |
| EPS (diluted) | 1.43 | 2.25 |
| Weighted avg. shares (diluted) | 65.44M | 80.60M |
| Balance sheet | ||
| Cash & equivalents | $302.54M | $155.33M |
| Short-term investments | $83.63M | $267.69M |
| Receivables | $43.50M | $36.34M |
| Inventory | $74.05M | $59.55M |
| Current assets | $698.62M | $714.45M |
| PP&E, net | $2.60M | $2.32M |
| Total assets | $766.43M | $785.67M |
| Current liabilities | $70.74M | $69.85M |
| Total liabilities | $83.23M | $81.85M |
| Shareholders' equity | $683.20M | $703.81M |
| Shares outstanding | 63.36M | 69.56M |
| Cash flow statement | ||
| Operating cash flow | $85.26M | $132.66M |
| Capital expenditure | $972,000 | $669,000 |
| Free cash flow | $84.28M | $132.00M |
| Investing cash flow | $186.03M | $162.21M |
| Financing cash flow | -$126.06M | -$282.77M |
| Depreciation & amortization | $695,000 | $728,000 |
| Stock-based compensation | $11.13M | $16.57M |
| Share buybacks | $127.44M | $285.38M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.